Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 2

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01184456Phase 2Completed

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

Role: collaborator

NCT02872688Not ApplicableCompleted

Influence of GanedenBC30 (Bacillus Coagulans GBI-30, 6086) on the Gut Microbiome in Healthy Adults

Role: collaborator

NCT01337609Phase 4Terminated

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

Role: collaborator

NCT00881322Not ApplicableCompleted

A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult

Role: collaborator

All 4 trials loaded